Kerrisdale Capital · research-note
AtriCure, Inc. (ATRC)
34 pages · 3 arc beats · 2 loops
AtriCure, Inc. (ATRC)
Kerrisdale Capital · 2020-09 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1246810121416182022242628303234
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 25 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
The Monster 5 slides 100% 5/5 slides 100% 5/5 slides · 30 hits — 0/5 slides
— 0/5 slides
40% 2/5 slides 100% 5/5 slides 20% 1/5 slides The Struggle 15 slides 100% 15/15 slides 100% 15/15 slides · 104 hits — 0/15 slides
— 0/15 slides
20% 3/15 slides 100% 15/15 slides 100% 15/15 slides The Victory 5 slides 100% 5/5 slides 100% 5/5 slides · 31 hits — 0/5 slides
20% 1/5 slides 20% 1/5 slides 100% 5/5 slides 100% 5/5 slides Slide inventory
34 every slide · same image gating as the playbook
01
This is a classic short-seller research note cover page.summarize
Open slide detailBeat · The Monster
03
The slide uses a strong thesis-driven opening statement typical of short-seller research reports.frame_problem
Open slide detailBeat · The Monster
04
The slide uses a narrative structure to discredit the CONVERGE IDE trial results by highlighting procedural flaws and superior alternatives.name_villain
Open slide detailBeat · The Monster
05
Short-seller research note page.expose_contradiction
06
This is a short-seller research note criticizing AtriCure's growth prospects and market positioning.name_villain
07
Research note discussing the technical advantages of PFA over RF/cryoablation and the diagnostic superiority of AcQMap over traditional mapping.summarize
08
The slide uses a short-seller thesis structure to argue that revenue growth has failed to translate into profitability or operating leverage.name_villain
09
Includes capitalization table, financial results table, and medical background on AF.establish_context
10
The slide explains the clinical rationale for AtriCure's products (ablation and AtriClip) by detailing the anatomy of the left atrial appendage and its role in establish_context
11
Includes footnotes referencing medical literature on atrial fibrillation treatments.diagnose_problem
12
The slide uses anatomical diagrams to illustrate the difference in ablation coverage between the two study arms.compare_peers
13
This is a research note from Kerrisdale Capital criticizing AtriCure's strategic pivot to hybrid procedures.name_villain
14
The slide uses a narrative structure to expose the failure of clinical trials and the resulting strategic shift.diagnose_problem
15
Critique of AtriCure's CONVERGE trial, specifically challenging the control group comparability.preempt_rebuttal
16
The slide uses clinical study data to challenge the validity of the Convergent trial's control group by showing superior outcomes for modern catheter-based PW apreempt_rebuttal
17
This is a standard text-heavy research report page with bulleted data points and footnotes.illustrate_case
18
The slide functions as a 'short-thesis' critique, specifically targeting the viability of the Convergent procedure by highlighting the misalignment of incentivename_villain
19
Includes a direct quote from AtriCure CEO Michael Carrel (May 2020) which is then countered by the author's analysis.name_villain
20
The slide uses a quote from a 2010 conference to contrast with 2020 data, arguing that the company's narrative is disingenuous.expose_contradiction
21
The slide uses academic citations to systematically dismantle the company's growth narrative.expose_contradiction
22
The slide uses a bulleted list to systematically dismantle the credibility of a research study.expose_contradiction
23
The slide uses a short-seller research note style to discredit the company's growth narrative and highlight the lack of operating leverage.name_villain
24
The text argues that the business is structurally unprofitable due to high R&D and SG&A costs that do not scale with revenue growth.analyze_data
25
Includes specific footnotes (21, 22) challenging the company's interpretation of the STAR AF II trial results.expose_contradiction
Open slide detailLoop · Cost Of Inaction
26
This slide provides background context on medical device innovation in cardiac ablation, citing specific clinical trials and studies.establish_context
Open slide detailLoop · Cost Of Inaction
27
The slide provides a detailed technical rationale for why PFA is superior to RF or cryo-ablation, focusing on the mechanism of electroporation.frame_problem
28
The slide discusses the clinical performance of Farapulse's PFA catheter and its potential impact on the cardiac ablation market and competitors like AtriCure.analyze_data
29
The slide uses a narrative structure to contrast clinical trial data with AtriCure's market claims.expose_contradiction
30
The slide discusses the technical advantages of non-contact charge-density mapping over traditional PVI ablation and cites clinical trial results.analyze_data
31
This is a text-heavy research note conclusion page.summarize
32
The slide uses a narrative-heavy format to dismantle the company's growth thesis.expose_contradiction